Skip to main content
SpringerLink
Log in
Book cover

Thrombosis and Embolism: from Research to Clinical Practice pp 285–306Cite as

Thrombosis and von Willebrand Factor

  • Chapter
  • First Online:

Part of the book series: Advances in Experimental Medicine and Biology ((AIM,volume 906))

Abstract

One of the key players in both hemostasis and thrombosis is von Willebrand factor (vWF), which demonstrates a duality between these two processes. Thrombus is structured by numerous elements, including endothelial cells, platelets, plasma proteins and shear stress alteration. In circulation, once a vessel wall is injured, collagen is exposed and platelets attach to the site of injury. Accordingly, vWF mediates adherence of platelets to the damaged vessel wall by binding both to the collagen and platelet receptor. A growing body of data also indicates a role for neutrophil extracellular traps (NETs) in human thrombosis as scaffolds for vWF, promoting thrombosis. VWF also mediates the protection of factor VIII, a main cofactor of the intrinsic clotting pathway. Since vWF plays a critical role in both thrombotic and bleeding events, a decreased plasma level of this factor may point to a bleeding disorder, while an elevated plasma level may predict occurrence of thrombosis. Since thrombotic events are the foremost cause of death, inhibiting the vWF activity would be a novel prophylaxis to reduce these events. Though, accumulated data have made vWF a promising focus for research on cardiovascular diseases (CVD). This chapter, however, aims to clarify the role of vWF in thrombus formation and pathogenesis of thrombosis.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   139.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   179.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   179.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Uncategorized References

  1. Arya M, Anvari B, Romo GM, Cruz MA, Dong JF, McIntire LV et al (2002) Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers. Blood 99(11):3971–3977

    Article  CAS  PubMed  Google Scholar 

  2. Chauhan AK, Kisucka J, Brill A, Walsh MT, Scheiflinger F, Wagner DD (2008) ADAMTS13: a new link between thrombosis and inflammation. J Exp Med 205(9):2065–2074

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Zimmerman TS, Ratnoff OD, Powell AE (1971) Immunologic differentiation of classic hemophilia (factor VIII deficiency) and von Willebrand’s disease: with observations on combined deficiencies of antihemophilic factor and proaccelerin (factor V) and on an acquired circulating anticoagulant against antihemophilic factor. J Clin Investig 50(1):244

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Mossard JM, Wiesel ML, Cazenave JP, Grunebaum L, Drawin T, Kieny JR et al (1989) Relation of an increase of von Willebrand factor in the blood, acute myocardial infarction, unstable angina and coronary thrombosis. Arch Mal Coeur Vaiss 82(11):1813–1818

    CAS  PubMed  Google Scholar 

  5. Nichols TC, Samama CM, Bellinger DA, Roussi J, Reddick RL, Bonneau M et al (1995) Function of von Willebrand factor after crossed bone marrow transplantation between normal and von Willebrand disease pigs: effect on arterial thrombosis in chimeras. Proc Natl Acad Sci U S A 92(7):2455–2459

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Brinkhous KM, Reddick RL, Read MS, Nichols TC, Bellinger DA, Griggs TR (1991) von Willebrand factor and animal models: contributions to gene therapy, thrombotic thrombocytopenic purpura, and coronary artery thrombosis. Mayo Clin Proc 66(7):733–742

    Article  CAS  PubMed  Google Scholar 

  7. Nichols TC, Bellinger DA, Reddick RL, Read MS, Koch GG, Brinkhous KM et al (1991) Role of von Willebrand factor in arterial thrombosis. Studies in normal and von Willebrand disease pigs. Circulation 83(6 Suppl):IV56–IV64

    CAS  PubMed  Google Scholar 

  8. von Meyer D (1993) Willebrand factor: a target for inhibition of thrombosis. Nouv Rev Fr Hematol 35(3):255–257

    CAS  PubMed  Google Scholar 

  9. Fay PJ, Coumans JV, Walker FJ (1991) von Willebrand factor mediates protection of factor VIII from activated protein C-catalyzed inactivation. J Biol Chem 266(4):2172–2177

    CAS  PubMed  Google Scholar 

  10. Andreotti F, Hackett DR, Haider AW, Roncaglioni MC, Davies GJ, Beacham JL et al (1992) Von Willebrand factor, plasminogen activator inhibitor-1 and C-reactive protein are markers of thrombolytic efficacy in acute myocardial infarction. Thromb Haemost 68(6):678–682

    CAS  PubMed  Google Scholar 

  11. Shahidi M (2010) The inflammatory and thrombotic effects of C-reactive protein on endothelial cells. University of Surrey, Guildford

    Google Scholar 

  12. Jansson JH, Nilsson TK, Johnson O (1991) von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 66(5):351–355

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Wiman B, Andersson T, Hallqvist J, Reuterwall C, Ahlbom A, deFaire U (2000) Plasma levels of tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor are significant risk markers for recurrent myocardial infarction in the Stockholm Heart Epidemiology Program (SHEEP) study. Arterioscler Thromb Vasc Biol 20(8):2019–2023

    Article  CAS  PubMed  Google Scholar 

  14. Tanis B, Algra A, van der Graaf Y, Helmerhorst F, Rosendaal F (2006) Procoagulant factors and the risk of myocardial infarction in young women. Eur J Haematol 77(1):67–73

    Article  CAS  PubMed  Google Scholar 

  15. Bauer AT, Suckau J, Frank K, Desch A, Görtz L, Wagner AH et al (2015) von Willebrand factor fibers promote cancer-associated platelet aggregation in malignant melanoma of mice and humans. Blood 125(20):3153–3163

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Shahidi M, Razavi M, Hayat P (2015) Induction of endothelial cell proliferation and von Willebrand factor (vWF) secretion by leukemic plasma of patients with chronic lymphocytic leukemia before and after inhibition of NF-kB. Blood Coagul Fibrinolysis (in press)

    Google Scholar 

  17. van den Dries LW, Gruters RA, der Borden SB H–v, Kruip MJ, de Maat MP, van Gorp EC et al (2015) von Willebrand Factor is elevated in HIV patients with a history of thrombosis. Front Microbiol 72:20. doi:10.3389/fmicb.2015.00180

  18. McKusick VA, Amberger JS (1994) The morbid anatomy of the human genome: chromosomal location of mutations causing disease (update 1 December 1993). J Med Genet 31(4):265–279

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Keightley AM, Lam YM, Brady JN, Cameron CL, Lillicrap D (1999) Variation at the von Willebrand factor (vWF) gene locus is associated with plasma vWF:Ag levels: identification of three novel single nucleotide polymorphisms in the vWF gene promoter. Blood 93(12):4277–4283

    CAS  PubMed  Google Scholar 

  20. Harvey PJ, Keightley AM, Lam YM, Cameron C, Lillicrap D (2000) A single nucleotide polymorphism at nucleotide− 1793 in the von Willebrand factor (VWF) regulatory region is associated with plasma VWF: Ag levels. Br J Haematol 109(2):349–353

    Article  CAS  PubMed  Google Scholar 

  21. Bongers TN, de Maat MP, van Goor M-LP, Bhagwanbali V, van Vliet HH, García EBG et al (2006) High von Willebrand factor levels increase the risk of first ischemic stroke influence of ADAMTS13, inflammation, and genetic variability. Stroke 37(11):2672–2677

    Article  CAS  PubMed  Google Scholar 

  22. Momi S, Tantucci M, Van Roy M, Ulrichts H, Ricci G, Gresele P (2013) Reperfusion of cerebral artery thrombosis by the GPIb–VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs. Blood 121(25):5088–5097

    Article  CAS  PubMed  Google Scholar 

  23. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE (1996) Shear-dependent changes in the three-dimensional structure of human von Willebrand factor. Blood 88(8):2939–2950

    CAS  PubMed  Google Scholar 

  24. Lenting P, Pegon J, Christophe O, Denis C (2010) Factor VIII and von Willebrand factor–too sweet for their own good. Haemophilia 16(s5):194–199

    Article  CAS  PubMed  Google Scholar 

  25. Weibel ER, Palade GE (1964) New cytoplasmic components in arterial endothelia. J Cell Biol 23(1):101–112

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Nowak A, McKinnon T, Hughes J, Chion A, Laffan M (2014) The O‐linked glycans of human von Willebrand factor modulate its interaction with ADAMTS‐13. J Thromb Haemost 12(1):54–61

    Article  CAS  PubMed  Google Scholar 

  27. Sporn LA, Marder VJ, Wagner DD (1986) Inducible secretion of large, biologically potent von Willebrand factor multimers. Cell 46(2):185–190

    Article  CAS  PubMed  Google Scholar 

  28. Cramer EM, Breton-Gorius J, Beesley JE, Martin JF (1988) Ultrastructural demonstration of tubular inclusions coinciding with von Willebrand factor in pig megakaryocytes. Blood 71(6):1533–1538

    CAS  PubMed  Google Scholar 

  29. Blair P, Flaumenhaft R (2009) Platelet α-granules: basic biology and clinical correlates. Blood Rev 23(4):177–189

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Koutts J, Walsh PN, Plow EF, Fenton JW 2nd, Bouma BN, Zimmerman TS (1978) Active release of human platelet factor VIII-related antigen by adenosine diphosphate, collagen, and thrombin. J Clin Invest 62(6):1255–1263

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Wagner DD (1990) Cell biology of von Willebrand factor. Annu Rev Cell Biol 6(1):217–242

    Article  CAS  PubMed  Google Scholar 

  32. Denis CV (2002) Molecular and cellular biology of von Willebrand factor. Int J Hematol 75(1):3–8

    Article  CAS  PubMed  Google Scholar 

  33. Mendolicchio GL, Ruggeri ZM (2005) New perspectives on von Willebrand factor functions in hemostasis and thrombosis. Semin Hematol 42(1):5–14

    Google Scholar 

  34. Ruggeri ZM (2004) Type IIB, von Willebrand disease: a paradox explains how von Willebrand factor works. J Thrombosis Haemost JTH 2(1):2–6

    Article  CAS  PubMed  Google Scholar 

  35. Mendolicchio GL, Ruggeri ZM (2005) New perspectives on von Willebrand factor functions in hemostasis and thrombosis. Semin Hematol 42(1):5–14

    Article  CAS  PubMed  Google Scholar 

  36. Xiang Y, Cheng J, Wang D, Hu X, Xie Y, Stitham J et al (2015) Hyperglycemia repression of miR-24 coordinately upregulates endothelial cell expression and secretion of Von Willebrand Factor. Blood 2015:blood-2015-01-620278

    Google Scholar 

  37. Chen J, Zhou H, Diacovo A, Zheng XL, Emsley J, Diacovo TG (2014) Exploiting the kinetic interplay between GPIbalpha-VWF binding interfaces to regulate hemostasis and thrombosis. Blood 124(25):3799–3807

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD et al (2010) Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci 107(36):15880–15885

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Brill A, Fuchs T, Savchenko A, Thomas G, Martinod K, De Meyer S et al (2012) Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 10(1):136–144

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Fuchs TA, Bhandari AA, Wagner DD (2011) Histones induce rapid and profound thrombocytopenia in mice. Blood 118(13):3708–3714

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Martinod K, Wagner DD (2014) Thrombosis: tangled up in NETs. Blood 123(18):2768–2776

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Grässle S, Huck V, Pappelbaum KI, Gorzelanny C, Aponte-Santamaría C, Baldauf C et al (2014) von Willebrand factor directly interacts with DNA from neutrophil extracellular traps. Arterioscler Thromb Vasc Biol 34(7):1382–1389

    Article  PubMed  CAS  Google Scholar 

  43. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR (1987) The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69(6):1691–1695

    CAS  PubMed  Google Scholar 

  44. Souto JC, Almasy L, Muñiz-Diaz E, Soria JM, Borrell M, Bayén L et al (2000) Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time. Arterioscler Thromb Vasc Biol 20(8):2024–2028

    Article  CAS  PubMed  Google Scholar 

  45. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345(8943):152–155

    Article  CAS  PubMed  Google Scholar 

  46. O’Donnell J, Laffan M (2001) The relationship between ABO histo‐blood group, factor VIII and von Willebrand factor. Transfus Med 11(4):343–351

    Article  PubMed  Google Scholar 

  47. Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontara E et al (2008) A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 111(7):3540–3545

    Article  CAS  PubMed  Google Scholar 

  48. O’Donnell JS, McKinnon TA, Crawley JT, Lane DA, Laffan MA (2005) Bombay phenotype is associated with reduced plasma-VWF levels and an increased susceptibility to ADAMTS13 proteolysis. Blood 106(6):1988–1991

    Article  PubMed  CAS  Google Scholar 

  49. O’Donnell J, Boulton FE, Manning RA, Laffan MA (2002) Genotype at the secretor blood group locus is a determinant of plasma von Willebrand factor level. Br J Haematol 116(2):350–356

    Article  PubMed  Google Scholar 

  50. Schleef M, Strobel E, Dick A, Frank J, Schramm W, Spannagl M (2005) Relationship between ABO and Secretor genotype with plasma levels of factor VIII and von Willebrand factor in thrombosis patients and control individuals. Br J Haematol 128(1):100–107

    Article  PubMed  Google Scholar 

  51. Leclerc J-M, David M, Ducruet T, Robitaille N (2013) ABO group as a thrombotic risk factor in children with acute lymphoblastic leukemia: a retrospective study of 523 pediatric patients. Blood 122(21):2370

    Google Scholar 

  52. Muellner SK, Haut ER, Streiff MB, Holcomb JB, Cotton BA (2011) ABO blood group as a potential risk factor for venous thromboembolism in acutely injured patients. Thromb Haemost 105(1):5

    Article  CAS  PubMed  Google Scholar 

  53. Franchini M, Rossi C, Frattini F, Crestani S, Sissa C, Meschieri M et al (2014) ABO blood group and risk of peripheral arterial thrombosis in patients with atrial fibrillation: a single center survey. J Thromb Thrombolysis 38(1):30–31

    Article  PubMed  Google Scholar 

  54. Conlan MG, Folsom AR, Finch A, Davis C, Sorlie P, Marcucci G et al (1993) Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) study. Thromb Haemost 70(3):380–385

    CAS  PubMed  Google Scholar 

  55. Albánez S, Michels A, Sponagle K, Lillicrap D (2014) Age-related increases in plasma factor VIII and Von Willebrand factor in a C57BL/6 mouse model are associated with increased factor VIII and Von Willebrand factor gene expression and reduced expression of the clearance receptor, Stabilin-2. Blood 124(21):4228

    Google Scholar 

  56. Furlan M, Robles R, Lamie B (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87(10):4223–4234

    CAS  PubMed  Google Scholar 

  57. Wu J-J, Fujikawa K, McMullen BA, Chung DW (2006) Characterization of a core binding site for ADAMTS-13 in the A2 domain of von Willebrand factor. Proc Natl Acad Sci 103(49):18470–18474

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Tsai H (1996) Physiologic cleavage of von Willebrand factor by a plasma protease. Blood 87(10):4235–4244

    CAS  PubMed  Google Scholar 

  59. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K (2001) Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276(44):41059–41063

    Article  CAS  PubMed  Google Scholar 

  60. Lu RN, Yang S, Wu HM, Zheng XL (2015) Unconjugated bilirubin inhibits proteolytic cleavage of von Willebrand factor by ADAMTS13 protease. J Thromb Haemost 13(6):1064–1072

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Dong J-f, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN et al (2002) ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100(12):4033–4039

    Article  CAS  PubMed  Google Scholar 

  62. Batlle J, Lopez-Fernandez MF, Lopez-Borrasca A, Lopez-Berges C, Dent JA, Berkowitz SD et al (1987) Proteolytic degradation of von Willebrand factor after DDAVP administration in normal individuals. Blood 70(1):173–176

    CAS  PubMed  Google Scholar 

  63. Bowen DJ, MacLean RM, Pellard S, Collins PW (2001) High concentrations of coagulation factor VIII and thrombosis: is the factor VIII-binding domain of von Willebrand factor implicated? Br J Haematol 113(3):655–657

    Article  CAS  PubMed  Google Scholar 

  64. Fujikawa K, Suzuki H, McMullen B, Chung D (2001) Purification of human von Willebrand factor–cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98(6):1662–1666

    Article  CAS  PubMed  Google Scholar 

  65. Ruggeri Z, Mendolicchio G (2015) Interaction of von Willebrand factor with platelets and the vessel wall. Hamostaseologie 35(3):211–224

    Article  CAS  PubMed  Google Scholar 

  66. Zhao B-Q, Chauhan AK, Canault M, Patten IS, Yang JJ, Dockal M et al (2009) von Willebrand factor–cleaving protease ADAMTS13 reduces ischemic brain injury in experimental stroke. Blood 114(15):3329–3334

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Rauch A, Wohner N, Christophe OD, Denis CV, Susen S, Lenting PJ (2013) On the versatility of von Willebrand factor. Mediterr J Hematol Infect Dis 5(1):e2013046

    Article  PubMed  PubMed Central  Google Scholar 

  68. Zheng XL (2015) ADAMTS13 and von Willebrand factor in thrombotic thrombocytopenic purpura. Annu Rev Med 66:211–225

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Sonneveld MA, de Maat MP, Leebeek FW (2014) Von Willebrand factor and ADAMTS13 in arterial thrombosis: a systematic review and meta-analysis. Blood Rev 28(4):167–178

    Article  CAS  PubMed  Google Scholar 

  70. Williams SB, McKeown LP, Krutzsch H, Hansmann K, Gralnick HR (1994) Purification and characterization of human platelet von Willebrand factor. Br J Haematol 88(3):582–591

    Article  CAS  PubMed  Google Scholar 

  71. McGrath RT, McRae E, Smith OP, O’Donnell JS (2010) Platelet von Willebrand factor – structure, function and biological importance. Br J Haematol 148(6):834–843

    Article  CAS  PubMed  Google Scholar 

  72. Gralnick HR, Rick ME, McKeown LP, Williams SB, Parker RI, Maisonneuve P et al (1986) Platelet von Willebrand factor: an important determinant of the bleeding time in type I von Willebrand’s disease. Blood 68(1):58–61

    CAS  PubMed  Google Scholar 

  73. Nichols TC, Bellinger DA, Reddick RL, Smith SV, Koch GG, Davis K et al (1993) The roles of von Willebrand factor and factor VIII in arterial thrombosis: studies in canine von Willebrand disease and hemophilia A. Blood 81(10):2644–2651

    CAS  PubMed  Google Scholar 

  74. McGrath RT, van den Biggelaar M, Byrne B, O’Sullivan JM, Rawley O, O’Kennedy R et al (2013) Altered glycosylation of platelet-derived von Willebrand factor confers resistance to ADAMTS13 proteolysis. Blood 122(25):4107–4110

    Article  CAS  PubMed  Google Scholar 

  75. Chow TW, Hellums JD, Moake JL, Kroll M (1992) Shear stress-induced von Willebrand factor binding to platelet glycoprotein Ib initiates calcium influx associated with aggregation. Blood 80(1):113–120

    CAS  PubMed  Google Scholar 

  76. Mazzucato M, Cozzi MR, Pradella P, Ruggeri ZM, De Marco L (2004) Distinct roles of ADP receptors in von Willebrand factor–mediated platelet signaling and activation under high flow. Blood 104(10):3221–3227

    Article  CAS  PubMed  Google Scholar 

  77. Westein E, van der Meer AD, Kuijpers MJ, Frimat J-P, van den Berg A, Heemskerk JW (2013) Atherosclerotic geometries exacerbate pathological thrombus formation poststenosis in a von Willebrand factor-dependent manner. Proc Natl Acad Sci 110(4):1357–1362

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Vergauwe RM, Uji-i H, De Ceunynck K, Vermant J, Vanhoorelbeke K, Hofkens J (2014) Shear-stress-induced conformational changes of von Willebrand factor in a water–glycerol mixture observed with single molecule microscopy. J Phys Chem B 118(21):5660–5669

    Article  CAS  PubMed  Google Scholar 

  79. Nowak AA, Canis K, Riddell A, Laffan MA, McKinnon TA (2012) O-linked glycosylation of von Willebrand factor modulates the interaction with platelet receptor glycoprotein Ib under static and shear stress conditions. Blood 120(1):214–222

    Article  CAS  PubMed  Google Scholar 

  80. Chan CHH, Pieper IL, Fleming S, Friedmann Y, Foster G, Hawkins K et al (2014) The effect of shear stress on the size, structure, and function of human von Willebrand factor. Artif Organs 38(9):741–750

    Article  CAS  PubMed  Google Scholar 

  81. Lazzari MA, Sanchez-Luceros A, Woods AI, Alberto MF, Meschengieser SS (2012) Von Willebrand factor (VWF) as a risk factor for bleeding and thrombosis. Hematology 17(Suppl 1):S150–S152

    CAS  PubMed  Google Scholar 

  82. Diaz JA, Wrobleski SK, Alvarado CM, Hawley AE, Doornbos NK, Lester PA et al (2015) P-selectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor. Arterioscler Thromb Vasc Biol 35(4):829–837

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Dmitrieva NI, Burg MB (2014) Secretion of von Willebrand factor by endothelial cells links sodium to hypercoagulability and thrombosis. Proc Natl Acad Sci 111(17):6485–6490

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Kageyama S, Yamamoto H, Nakazawa H, Yoshimoto R (2001) Anti-human vWF monoclonal antibody, AJvW-2 Fab, inhibits repetitive coronary artery thrombosis without bleeding time prolongation in dogs. Thromb Res 101(5):395–404

    Article  CAS  PubMed  Google Scholar 

  85. Yamamoto J, Ishii I, Okita N, Sasaki Y, Yamashita T, Matsuoka A et al (1997) The differential involvement of von Willebrand factor, fibrinogen and fibronectin in acute experimental thrombosis in rat cerebral and mesenteric microvessels. Jpn J Physiol 47(5):431–441

    Article  CAS  PubMed  Google Scholar 

  86. Hoylaerts MF, Thys C, Arnout J, Vermylen J (1998) Recurrent arterial thrombosis linked to autoimmune antibodies enhancing von Willebrand factor binding to platelets and inducing Fc gamma RII receptor-mediated platelet activation. Blood 91(8):2810–2817

    CAS  PubMed  Google Scholar 

  87. Hosler GA, Cusumano AM, Hutchins GM (2003) Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 127(7):834–839

    PubMed  Google Scholar 

  88. Turner N, Sartain S, Moake J (2015) Ultralarge von Willebrand factor–induced platelet clumping and activation of the alternative complement pathway in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndromes. Hematology/Oncology Clinics of North America, Willey online library

    Google Scholar 

  89. Bettoni G, Palla R, Valsecchi C, Consonni D, Lotta L, Trisolini S et al (2012) ADAMTS‐13 activity and autoantibodies classes and subclasses as prognostic predictors in acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 10(8):1556–1565

    Google Scholar 

  90. Moake JL, Chow TW (1998) Increased von Willebrand factor (vWf) binding to platelets associated with impaired vWf breakdown in thrombotic thrombocytopenic purpura. J Clin Apher 13(3):126–132

    Article  CAS  PubMed  Google Scholar 

  91. Lotta LA, Valsecchi C, Pontiggia S, Mancini I, Cannavo A, Artoni A et al (2014) Measurement and prevalence of circulating ADAMTS13-specific immune complexes in autoimmune thrombotic thrombocytopenic purpura. J Thrombosis Haemost JTH 12(3):329–336

    Article  CAS  PubMed  Google Scholar 

  92. Shamseddine A, Chehal A, Usta I, Salem Z, El‐Saghir N, Taher A (2004) Thrombotic thrombocytopenic purpura and pregnancy: report of four cases and literature review. J Clin Apher 19(1):5–10

    Article  PubMed  Google Scholar 

  93. Riviere E, Saint‐Léger M, James C, Delmas Y, Clouzeau B, Bui N et al (2015) Platelet transfusion and catheter insertion for plasma exchange in patients with thrombotic thrombocytopenic purpura and a low platelet count. Transfusion 55(7):1798–1802

    Article  PubMed  Google Scholar 

  94. Gerritsen HE, Turecek PL, Schwarz HP, Lämmle B, Furlan M (1999) Assay of von Willebrand Factor (vWF)-cleaving protease based on decreased collagen binding affinity of degraded vWF a tool for the diagnosis of Thrombotic Thrombocytopenic Purpura (TTP). Thromb Haemost 82(5):1386–1389

    CAS  PubMed  Google Scholar 

  95. Ruggeri ZM, Zimmerman TS (1987) von Willebrand factor and von Willebrand disease [published erratum appears in Blood 1988 Mar; 71 (3): 830]. Blood 70(4):895–904

    CAS  PubMed  Google Scholar 

  96. Meijer P, Haverkate F (2006) An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemost 32(5):485–491

    Article  CAS  PubMed  Google Scholar 

  97. Meijer P, Haverkate F (eds) (2006) An external quality assessment program for von Willebrand factor laboratory analysis: an overview from the European concerted action on thrombosis and disabilities foundation. Semin Thromb Hemostasis 32(5):485–491

    Google Scholar 

  98. Flood VH, Gill JC, Morateck PA, Christopherson PA, Friedman KD, Haberichter SL et al (2011) Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD. Blood 117(6):e67–e74

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Debart PR, Tomas MMF, Nieto JIJ (2013) Process for obtaining a concentrate of Von Willebrand factor or a complex of factor VII/Von Willebrand factor and use of the same. Google Patents

    Google Scholar 

  100. Lenting PJ, Denis CV, Wohner N (2013) Von Willebrand factor and thrombosis: risk factor, actor and pharmacological target. Curr Vasc Pharmacol 11(4):448–456

    Article  CAS  PubMed  Google Scholar 

  101. Bugnicourt JM, Roussel B, Tramier B, Lamy C, Godefroy O (2007) Cerebral venous thrombosis and plasma concentrations of factor VIII and von Willebrand factor: a case control study. J Neurol Neurosurg Psychiatry 78(7):699–701

    Article  PubMed  Google Scholar 

  102. Pareti FI, Lattuada A, Bressi C, Zanobini M, Sala A, Steffan A et al (2000) Proteolysis of von Willebrand factor and shear stress-induced platelet aggregation in patients with aortic valve stenosis. Circulation 102(11):1290–1295

    Article  CAS  PubMed  Google Scholar 

  103. De Ceunynck K, Rocha S, Feys HB, De Meyer SF, Uji-i H, Deckmyn H et al (2011) Local elongation of endothelial cell-anchored von Willebrand factor strings precedes ADAMTS13 protein-mediated proteolysis. J Biol Chem 286(42):36361–36367

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  104. Roldán V, Marín F, Muiña B, Torregrosa JM, Hernández-Romero D, Valdés M et al (2011) Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol 57(25):2496–2504

    Article  PubMed  CAS  Google Scholar 

  105. Greisenegger S, Segal HC, Burgess AI, Poole DL, Mehta Z, Rothwell PM (2015) Biomarkers and mortality after transient ischemic attack and minor ischemic stroke population-based study. Stroke 46(3):659–666

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  106. Matsuda SS, Vaez R, Pinheiro PNB, Noguti MAE, Lourenço DM, Morelli VM (2013) The role of high Von Willebrand factor and low ADAMTS13 levels in the risk of venous thromboembolism. Blood 122(21):1128

    Google Scholar 

  107. Liu L, Ling J, Ma Z, Yuan Q, Pan J, Yang H (2015) Changes in von Willebrand factor and ADAMTS-13 in patients following arthroplasty. Mol Med Rep 11(4):3015–3020

    CAS  PubMed  Google Scholar 

  108. Schwameis M, Schorgenhofer C, Assinger A, Steiner M, Jilma B (2015) VWF excess and ADAMTS13 deficiency: a unifying pathomechanism linking inflammation to thrombosis in DIC, malaria, and TTP. Thromb Haemost 113(4):708–718

    Article  PubMed  Google Scholar 

  109. Luken BM, Turenhout EA, Kaijen PH, Greuter MJ, Pos W, van Mourik JA et al (2006) Amino acid regions 572–579 and 657–666 of the spacer domain of ADAMTS13 provide a common antigenic core required for binding of antibodies in patients with acquired TTP. Thromb Haemost 96(3):295–301

    CAS  PubMed  Google Scholar 

  110. Shahidi M, Barati M, Hayat P, Tavasoli B, Bakhshayesh M (2014) The in vitro effects of sodium salicylate on von Willebrand factor and C-reactive protein production by endothelial cells. Inflammopharmacology 22(6):367–372

    Article  CAS  PubMed  Google Scholar 

  111. Federici AB, Berkowitz SD, Zimmerman TS, Mannucci P (1992) Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. Blood 79(1):38–44

    CAS  PubMed  Google Scholar 

  112. Vanhoorelbeke K, Ulrichts H, de Walle GV, Fontayne A, Deckmyn H (2007) Inhibition of platelet glycoprotein Ib and its antithrombotic potential. Curr Pharm Des 13(26):2684–2697

    Article  CAS  PubMed  Google Scholar 

  113. Firbas C, Siller-Matula JM, Jilma B (2010) Targeting von Willebrand factor and platelet glycoprotein Ib receptor. Expert Rev Cardiovasc Ther 8(12):1689–1701

    Article  CAS  PubMed  Google Scholar 

  114. Bae O-N (2012) Targeting von Willebrand factor as a novel anti-platelet therapy; application of ARC1779, an Anti-vWF aptamer, against thrombotic risk. Arch Pharm Res 35(10):1693–1699

    Article  CAS  PubMed  Google Scholar 

  115. Cosmi B (2009) ARC-1779, a PEGylated aptamer antagonist of von Willebrand factor for potential use as an anticoagulant or antithrombotic agent. Curr Opin Mol Ther 11(3):322–328

    CAS  PubMed  Google Scholar 

  116. De Meyer SF, Stoll G, Wagner DD, Kleinschnitz C (2012) von Willebrand factor an emerging target in stroke therapy. Stroke 43(2):599–606

    Article  PubMed  CAS  Google Scholar 

  117. McEwan PA, Andrews RK, Emsley J (2009) Glycoprotein Ibα inhibitor complex structure reveals a combined steric and allosteric mechanism of von Willebrand factor antagonism. Blood 114(23):4883–4885

    Article  CAS  PubMed  Google Scholar 

  118. Hou Y, Reheman A, Li BX, Dai X, Yang Z, Qian F, Suppl 1 et al (2014) Development of a novel antithrombotic therapy targeting platelet GPIbα: assessment of anfibatide in vitro and in phase I clinical trial. Arterioscler Thromb Vasc Biol 34:A499–A499

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematology Department, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, 14155-6183, Iran

    Minoo Shahidi Ph.D.

Authors
  1. Minoo Shahidi Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Minoo Shahidi Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden

    Md. Shahidul Islam

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Shahidi, M. (2016). Thrombosis and von Willebrand Factor. In: Islam, M. (eds) Thrombosis and Embolism: from Research to Clinical Practice. Advances in Experimental Medicine and Biology(), vol 906. Springer, Cham. https://doi.org/10.1007/5584_2016_122

Download citation

  • DOI: https://doi.org/10.1007/5584_2016_122

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22107-6

  • Online ISBN: 978-3-319-22108-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation